Roche Executive Says Alzheimer’s Drug Will be Cheaper Than Aduhelm

Published on November 10, 2021

Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer’s drug, is already taking aim at rival Biogen Inc’s Aduhelm, saying that its medication would be priced competitively. Bill Anderson, head of pharmaceuticals at Roche, did not…

Read Full Article (External Site)